Table 2

Presence of anti-peptide IgG in sera from patients with SSc or SLE and healthy blood donors, according to the best cutoffs for discriminating ACA-positive from ACA-negative SSc patients

IgG specificity

Discriminating

SSc

SLE (n =46)

HBD (n =25)


cutoff (µg/ml)a

ACA+

(n = 75)

ACA+

(n =46)


Ap1-17+

>10.4

66 (88.0)

1 (2.2)

2 (4.3)

3 (12.0)

Ap17-30+

>1.2

62 (82.6)

2 (4.3)

4 (8.7)

1 (4.0)

FOXE3p53-62+

>74.5

40 (53.3)

5 (10.9)

13 (28.3)

1 (4.0)

FOXE3p53-62+ and Ap1-17+ or Ap17-30+

40 (100)b

0 (0) b

3 (23.1) b

1 (100) b


Values are presented as n (%) from a sample of 121 patients with SSc, 46 patients with SLE, and 25 HBD. aCutoffs were defined using receiver operating characteristic analysis; bpercentage of FOXE3p53-62+ samples that were also positive for Ap1-17 and/or Ap17-30. ACA, anti-centromere-associated protein antibodies; SSc, systemic sclerosis; SLE, systemic lupus erythematosus; HBD, healthy blood donors.

Perosa et al. Arthritis Research & Therapy 2013 15:R72   doi:10.1186/ar4249

Open Data